{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:14:55Z","timestamp":1788178495366,"version":"build-2803163510"},"reference-count":19,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:p>Background: Chronic deep vein thrombosis (DVT) is a persistent clinical condition that often results in venous obstruction, post-thrombotic syndrome and impaired quality of life. Conventional endovascular dilation is limited by elastic recoil and high rates of restenosis caused by neointimal hyperplasia. Paclitaxel-based localized venous therapy enables targeted delivery of antiproliferative agents directly to the venous wall, offering a pharmacological strategy to suppress pathological vascular remodeling and improve long-term outcomes. Objectives: To evaluate the efficacy and safety of paclitaxel-based localized venous therapy in improving long-term venous patency and reducing restenosis in patients with chronic DVT, compared with conventional angioplasty. Methods: This retrospective multicenter study analyzed patient records from three vascular centers between 2019 and 2024. A total of 245 patients with chronic DVT were included, of whom 127 received paclitaxel-based localized therapy and 118 underwent conventional angioplasty. Primary endpoints were venous patency and restenosis rates. Secondary endpoints included freedom from clinically driven reintervention and quality-of-life outcomes. Clinical and imaging follow-up was conducted at baseline and at 6, 12 and 24 months. Multivariate regression analysis was performed using SPSS version 28. Results: At 24-month follow-up, primary venous patency was significantly higher in the paclitaxel-based therapy group than in the conventional angioplasty group (82.7% vs. 61.9%), with lower restenosis rates (11.8% vs. 29.7%). Paclitaxel-based localized therapy was associated with greater freedom from reintervention (hazard ratio 0.42; 95% CI 0.29\u20130.61; p &lt; 0.001). Quality-of-life scores improved significantly in the paclitaxel group (mean difference 14.3 points; p = 0.002). No significant differences were observed in major complications or thrombotic events between groups. Conclusion: Paclitaxel-based localized therapy provides superior long-term venous patency, reduced restenosis and improved quality of life without compromising safety. These findings highlight the pharmaceutical relevance of localized antiproliferative drug delivery in the management of chronic venous disease.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.8.237.1","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:08:57Z","timestamp":1781010537000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Clinical Outcomes Of Paclitaxel-Coated Balloon Angioplasty In Chronic Deep Vein Thrombosis: A Multicenter Retrospective Study"],"prefix":"10.36721","author":[{"given":"Orhan","family":"Rodoplu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"ref0","unstructured":"Almeida JF, Costa R, Pereira M and Santos L (2023). Endovascular drug delivery strategies in chronic venous disease management. J. Vasc. Interv. Radiol., 34(6): 881\u2013889."},{"key":"ref1","unstructured":"Anderson P, Lewis J and Carter M (2023). Mechanisms of paclitaxel-mediated inhibition of venous neointimal hyperplasia. J. Vasc. Res., 60(4): 211\u2013219."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Barco S, Sebastian T, Voci D, Engelberger RP, Grigorean A, Holy E, Leeger C, Munger M, Periard D, Probst E and Spescha R (2022). Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: A structured protocol summary of the \u201cSirPAD\u201d randomized controlled trial. Trials., 23(1): 334.","DOI":"10.1186\/s13063-022-06242-8"},{"key":"ref3","unstructured":"Chen Y, Zhao H, Liu X and Wang J (2024). Advances in paclitaxel-coated balloon therapy for chronic venous obstruction. Front. Cardiovasc. Med., 11: 1452217."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Cui HJ and Wu YF (2024). The efficacy of drug-coated balloons and drug-eluting stents in infrapopliteal revascularization: A meta-analysis. J. Endovasc. Ther., 31: 15266028231222385.","DOI":"10.1177\/15266028231222385"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"DePietro DM and Trerotola SO (2023). Choosing the right treatment for the right lesion, Part II: A narrative review of drug-coated balloon angioplasty and its evolving role in dialysis access maintenance. Cardiovasc. Diagn. Ther., 13(1): 233\u2013244.","DOI":"10.21037\/cdt-22-497"},{"key":"ref6","unstructured":"Garcia M, Velasquez P, Rivera D and Torres J (2023). Functional recovery after drug-coated balloon angioplasty in chronic venous insufficiency. Vasc. Endovascular Surg., 57(8): 741\u2013748."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ilyas S and Powell RJ (2022). Management of the no-option foot: Deep vein arterialization. Semin. Vasc. Surg., 35(2): 210\u2013218.","DOI":"10.1053\/j.semvascsurg.2022.05.002"},{"key":"ref8","unstructured":"Kim SY, Park JK and Lee DH (2023). Post-procedural anticoagulation strategies following venous endovascular intervention. Ann. Vasc. Surg., 91: 188\u2013196."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lei J, Pu H, Zhang L, Zeng C, Peng Z, Wu Z, Jiang Y, Wang R and Lu X (2024). Drug-coated balloon therapy for in-stent restenosis in patients with iliofemoral deep vein thrombosis: A single-arm observational study. Catheter. Cardiovasc. Interv., 103(5): 752\u2013757.","DOI":"10.1002\/ccd.30975"},{"key":"ref10","unstructured":"Lopez R, Martinez A and Cruz P (2024). Emerging pharmacological technologies in venous endovascular therapy. Int. Angiol., 43(2): 120\u2013128."},{"key":"ref11","unstructured":"Lv S, Wei G, Shi X, Xu Q and Li X (2024). Efficacy and safety of drug-coated balloon in elderly patients with intrastent restenosis after lower extremity arteriosclerotic obliterans following Rotarex thrombus removal. Altern. Ther. Health Med., 30(2): 178\u2013182."},{"key":"ref12","unstructured":"Miller R, Zhang Y and Thompson K (2024). Antiproliferative drug delivery systems in chronic venous intervention. Vasc. Pharmacol., 158: 107312."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Moreno-S\u00e1nchez T, Moreno-Ram\u00edrez M and Machancoses FH (2024). Multicenter randomized controlled trial to assess the effectiveness of PASSEO-LUX DCB\u00ae drug-coated balloon compared to plain balloon angioplasty of arteriovenous fistulae for hemodialysis: Two-years results. J. Vasc. Access., 25: 11297298241272259.","DOI":"10.1177\/11297298241272259"},{"key":"ref14","unstructured":"Nakamura T, Ishikawa H and Sato M (2024). Combined pharmacomechanical approaches in chronic venous obstruction treatment. J. Endovasc. Ther., 31(3): 322\u2013330."},{"key":"ref15","unstructured":"Patel K, Sharma V and Mehta R (2023). Long-term patency outcomes following drug-coated balloon therapy in iliofemoral venous disease. Phlebology., 38(7): 512\u2013520."},{"key":"ref16","unstructured":"Rodriguez A, Fernandez M and Ruiz C (2022). Localized antiproliferative therapy in chronic venous intervention: Current evidence and future perspectives. Vascular., 30(5): 823\u2013831."},{"key":"ref17","unstructured":"Singh R, Verma P and Kulkarni S (2024). Imaging evaluation of chronic venous remodeling after endovascular therapy. Diagn. Interv. Radiol., 30(1): 45\u201353."},{"key":"ref18","unstructured":"Thompson L, Green D and Walker P (2025). Standardization of outcome reporting in chronic venous intervention trials. J. Vasc. Surg. Venous Lymphat. Disord., 13(1): 66\u201374."}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:23:23Z","timestamp":1788175403000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":19,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.8.237.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]}}}